Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review.

INTRODUCTION: Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising therapeutic option for obesity and metabolic disorders. METHODS: Systematic review following PRISMA guidelines across PubMed, Embase, and Cochrane. Included RCTs and observational studies. RESULTS: Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers. Well-tolerated, with low rates of hypoglycemia. Subgroups with higher BMI had greater benefits. DISCUSSION: Demonstrates consistent efficacy and safety across diverse populations; personalized approaches may optimize outcomes. CONCLUSION: Tirzepatide is effective, safe, and durable in managing obesity and metabolic disorders; long-term studies warranted.